屈螺酮炔雌醇片(Ⅱ)与炔雌醇醋酸环丙孕酮治疗多囊卵巢综合征疗效对比

Analysis on the correlation of therapeutic efficacies of drospirenone and ethinyl estradiol tablets(Ⅱ)and ethinyl estradiol cyproterone acetate on polycystic ovary syndrome

目的观察屈螺酮炔雌醇片(Ⅱ)与炔雌醇醋酸环丙孕酮治疗多囊卵巢综合征(PCOS)的疗效对比。方法选择2017年1月至2019年6月在南京医科大学附属无锡妇幼保健院就诊的60例PCOS患者作为研究对象进行随机分组,分为观察组30例与对照组30例,分别给予屈螺酮炔雌醇片(Ⅱ)、炔雌醇醋酸环丙孕酮治疗6个周期,观察治疗前后两组的体重指数(BMI)、痤疮、血压、血黄体生成素(LH)、卵泡刺激素(FSH)、睾酮(T)、血脂变化及月经、排卵情况。结果两组内治疗后BMI、收缩压及舒张压均无统计学意义(P>0.05),但痤疮情况均有改善,组间比较差异无统计学意义(P>0.05)。两组内治疗后血LH、T下降(P<0.05),但FSH治疗前后差异无统计学意义(P>0.05)。两组内治疗前后血脂差值差异均有统计学意义(P<0.05),且变化规律一致,除TG、TC外,治疗后HDL-C、LDL-C两组间差异有统计学意义(P<0.05)。组间规律月经率、排卵率差异比较无统计学意义(P>0.05)。结论屈螺酮炔雌醇片(Ⅱ)治疗PCOS临床效果满意,能改善患者的LH和T水平及痤疮、血脂代谢紊乱等症状,对患者体重无明显影响,值得临床推广应用。

Objective To observe the correlation of therapeutic efficacies of drospirenone and ethinyl estradiol tablets(Ⅱ)and ethinyl estradiol cyproterone acetate on polycystic ovary syndrome(PCOS).Methods A total of 60 cases of patients with PCOS admitted to Wuxi Maternal and Child Health Care Hospital Affiliated to Nanjing Medical University from January 2017 to June 2019 were selected and randomly divided into the drospirenone and control group(n=30)and the observation group(n=30).They were treated with drospirenone and ethinyl estradiol tablets(Ⅱ)and ethinyl estradiol cyproterone acetate respectively for 6 cycles.The body mass index(BMI),acne,blood pressure,luteinizing hormone(LH),follicle stimulating hormone(FSH),testosterone(T),blood lipid changes,menstruation and ovulation were observed between the two groups before and after treatment.Results After treatment,there were not significantly changes in BMI,systolic blood pressure and diastolic blood pressure between the two groups(P>0.05),but acne situation was improved in all(P<0.05),and there were no statistically significant differences between the two groups(P>0.05).After treatment,blood LH and T were decreased in both groups(P<0.05),but there was no statistical difference of blood FSH before and after treatment(P>0.05).The difference of blood lipid between the two groups before and after treatment was statistically significant(P<0.05),and the change rule was consistent.Except for TG and TC,the differences of HDL-C and LDL-C between the two groups after treatment were statistically significant(P<0.05).There was no statistically significant difference between menstruation and ovulation of the two groups(P>0.05).Conclusion The clinical efficacy of drospirenone and ethinyl estradiol tablets(Ⅱ)in the treatment of PCOS is satisfactory,which can improve the patients'LH and T levels,acne,dyslipidemia and other symptoms,and has no obvious impact on the weight of patients,so it is worthy of clinical promotion and application.